Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?

Pathology and Oncology Research

Volumn 9, Issue 1, 2003, Pages 20-23

  Ribeiro Silva, Alfredo ^a   Zamzelli Ramalho, Leandra N ^a   Garcia, Sérgio Britto ^a   Zucoloto, Sérgio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast; Ductal carcinoma is situ; Microinvasion; p63; Smooth muscle actin

Indexed keywords

ALPHA ACTIN; PROTEIN P53; PROTEIN P63; TUMOR MARKER;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MYOEPITHELIUM CELL; RELIABILITY; TUMOR VOLUME;

EID: 0038702158     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033709     Document Type: Article

References (23)

1. Barbareschi M, Pecciarini L, Cangi MG, et al.: P63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25: 1054-1060, 2001.
2. Damiani S, Ludvikova M, Tomasic G, et al: Myoepithelial cells and basal lamina in poorly differentiated is situ carcinoma of the breast. An immunocytochemical study. Virchows Arch 434: 227-234, 1999.
3. De Mascarel I, MacGrogan G, Mathoulin-Pelissier S, et al: Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 94: 2134-2142, 2002.
4. Di Como CJ, Urist MJ, Babayan I, et al: P63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8: 494-501, 2002.
5. Douglas-Jones AG, Gupta SK, Attanoos RL, et al: A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): Correlation with grade of associated invasive carcinoma. Histopathology 29: 397-409, 1996.
6. Foschini MP, Scarpellini F, Gown AM, et al.: Differential expression of myoepithelial markers in salivary, sweat and mammary glands. Int J Surg Pathol 8: 293-7, 2000.
7. Hoda SA, Prasad ML, Moore A, et al: Microinvasive carcinoma of the breast: can it be diagnosed reliably and its clinically significant? Histopathology 35: 468-472, 1999.
8. Irwin MS, Kaelin WG Jr: P53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12: 337-349, 2001.
9. Lazard D, Sastre X, Frid MG, et al: Expression of smooth musclespecific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci USA 90: 999-1003, 1993
10. Little NA, Jochemsen AG: P63. Int J Biochem Cell Biol 34: 6-9, 2002.
11. Miller NA, Chapman JA, Fish EB, et al: In situ carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma. Breast J 7: 292-302, 2001.
12. Mills AA, Zheng B, Wang XJ, et al: P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713, 1999.
13. Moritani S, Kushima R, Sugihara H, et al: Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 15: 397-405, 2002.
14. Polyak K: On the birth of breast cancer. Biochim Biophys Acta 1552: 1-13, 2001.
15. Reis-Filho JS, Albergaria A, Milanezi F, et al: Naked nuclei revisited: p63 immunoexpression. Diagn Cytopathol 27: 135-138, 2002.
16. Reis-Filho JS, Milanezi F, Amendoeira I, et al: P63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 55: 936-939, 2002.
17. Reis-Filho JS, Schmitt FC: Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 9: 280-289, 2002.
18. Signoretti S, Waltregny D, Dilks J, et al: P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775, 2000.
19. Silver SA, Tavassoli F: Mammary ductal carcinoma in situ with microinvasion. Cancer 82: 2382-2390, 1998.
20. Silverstein MJ, Poller DN, Waisman J, et al.: Prognostic classification of breast ductal carcinoma in situ. The Lancet 345: 1154-1157, 1995.
21. Skinner KA, Silverstein MJ: The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer 8: 33-45, 2001.
22. Smith GH, Chepko G: Mammary epithelial stem cells. Microsc Res Tech 52: 190-197, 2001.
23. Yang A, Schweitzer R, Sun D, et al: P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718, 1999.